LEADER 03252nam  2200565Ia 450 
001 9910777448303321
005 20230422045218.0
035   $a(CKB)1000000000450576
035   $a(EBL)3377586
035   $a(SSID)ssj0000137834
035   $a(PQKBManifestationID)11130104
035   $a(PQKBTitleCode)TC0000137834
035   $a(PQKBWorkID)10096235
035   $a(PQKB)10194402
035   $a(MiAaPQ)EBC3377586
035   $a(Au-PeEL)EBL3377586
035   $a(CaPaEBR)ebr10071903
035   $a(OCoLC)883573276
035   $a(EXLCZ)991000000000450576
100   $a20050324d2000      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aDeveloping technologies for early detection of breast cancer$b[electronic resource] $esummary of public workshop #2 /$fwritten by Laura Newman for the Committee on the Early Detection of Breast Cancer, National Cancer Policy Board, Institute of Medicine and Commission on Life Sciences, National Research Council
210   $aWashington, D.C. $cNational Academy Press$dc2000
215   $a1 online resource (53 p.)
300   $aSummary of a workshop held June 19-20, 2000.
311   $a0-309-57918-X 
327   $a""Developing Technologies for Early Detection of Breast Cancer""; ""Copyright""; ""Developing Technologies for Early Detection of Breast Cancer: Public Workshop Summary #2""; ""INTRODUCTION""; ""NIH Support for New Technologies""; ""Technology development initiatives""; ""Phased Innovation Award""; ""Technology development on the molecular analysis of cancer""; ""Cancer imaging""; ""Information systems development""; ""Unconventional Innovations Program""; ""Integrating detection and care""; ""Venture capital investment""
327   $a""Evidence Required for Approval by the Food and Drug Administration: FDA Regulation of In Vitro Diagnostic Requirements""""The FDA Process: An Industry Perspective""; ""ACRIN  A New NCI Cooperative Group for Clinical Trials of Medical Imaging""; ""Statistical Design for Clinical Trials""; ""Choosing appropriate study endpoints""; ""Coverage Issues from the Innovator's Perspective""; ""Medicare Coverage Advisory Committee""; ""National Cancer Institute's Breast Cancer Surveillance Consortium""; ""Using Risk Stratification to Tailor Screening Programs""
327   $a""Identifying the Customers of New Technologies and Disseminating New Research""""Access to Screening Mammography""; ""WORKSHOP SPEAKERS""
606   $aBreast$xCancer$xDiagnosis$vCongresses
606   $aBreast$xRadiography$vCongresses
606   $aMagnetic resonance imaging$vCongresses
615  0$aBreast$xCancer$xDiagnosis
615  0$aBreast$xRadiography
615  0$aMagnetic resonance imaging
676   $a616.99
700   $aNewman$b Laura$cM.A.$01520483
712 02$aNational Cancer Policy Board (U.S.).$bCommittee on the Early Detection of Breast Cancer.
712 02$aNational Research Council (U.S.).$bCommission on Life Sciences.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910777448303321
996   $aDeveloping technologies for early detection of breast cancer$93759090
997   $aUNINA